-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Adoptive cellular transfer (ACT) therapy is a tumor treatment method in which immune cells are first separated from the patient's body, activated, expanded and modified in vitro, and then reinjected into the patient's body for treatment.
Among them, adoptive T cell therapy has been successful in the treatment of hematological malignancies, and two chimeric antigen receptor T cell therapies (CAR-T) have been approved by the U.
S.
Food and Drug Administration in 2017 for B Treatment of cellular lymphoma (Yescarta) and acute lymphoblastic leukemia (Kymriah).
However, ACT therapy still has some potential problems that hinder its further widespread application.
First of all, the specific mechanism of ACT therapy to treat tumors is still unclear.
Secondly, its therapeutic effect on solid tumors is still very limited.
In addition, the systemic side effects and complicated procedures of ACT therapy are also major challenges for its clinical application.
The rapid development of nanotechnology provides new strategies for overcoming the above-mentioned challenges in ACT therapy.
The nanomedicine team of the Third Affiliated Hospital of Sun Yat-sen University summarized and introduced the recent progress of nanomaterials for tumor ACT treatment in detail, and summarized four types of nanomaterials used to optimize the key stages of ACT, including: (1) for in vitro amplification And multi-scale artificial antigen-presenting cells that activate adoptive T cells; (2) nanoparticles used to improve the transfection efficiency of tumor target sites; (3) used to engineer adoptively transferred cells to achieve cell tracking and promotion Nanomaterials for tumor infiltration and maintenance of in vivo functions; (4) Nanomaterials for in-situ editing of anti-tumor T cells in vivo.
In addition, the review also discussed the prospects and challenges of nanomaterials in the basic and clinical research of ACT therapy, providing references and guidelines for nanomaterial-based ACT cancer therapy.
WILEY paper information: Engineering Nano-Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment.
Chunxiong Zheng, Jiabin Zhang, Hon Fai Chan, Hanze Hu, Shixian Lv, Ning Na, Yu Tao, Mingqiang LiSmall Methods DOI: 10.
1002/smtd.
202001191 click on the bottom left Corner "Read the original text" to view the original text of the paper.
About SmallMethods Journal Small Methods, a journal of Wiley, is a high-level comprehensive journal founded in 2017.
The journal concentrates on the progress of experimental techniques related to sodium micron-scale materials, covering fields including materials science, biomedicine, chemistry, physics and other synthesis, characterization, and application technologies.
The latest impact factor is 12.
13.
Press and hold the QR code on the official WeChat platform of AdvancedScienceNewsWiley's scientific research information.
Follow us to share cutting-edge information｜Focus on scientific research trends to publish scientific research news or apply for information sharing, please contact: ASNChina@Wiley.
com
Among them, adoptive T cell therapy has been successful in the treatment of hematological malignancies, and two chimeric antigen receptor T cell therapies (CAR-T) have been approved by the U.
S.
Food and Drug Administration in 2017 for B Treatment of cellular lymphoma (Yescarta) and acute lymphoblastic leukemia (Kymriah).
However, ACT therapy still has some potential problems that hinder its further widespread application.
First of all, the specific mechanism of ACT therapy to treat tumors is still unclear.
Secondly, its therapeutic effect on solid tumors is still very limited.
In addition, the systemic side effects and complicated procedures of ACT therapy are also major challenges for its clinical application.
The rapid development of nanotechnology provides new strategies for overcoming the above-mentioned challenges in ACT therapy.
The nanomedicine team of the Third Affiliated Hospital of Sun Yat-sen University summarized and introduced the recent progress of nanomaterials for tumor ACT treatment in detail, and summarized four types of nanomaterials used to optimize the key stages of ACT, including: (1) for in vitro amplification And multi-scale artificial antigen-presenting cells that activate adoptive T cells; (2) nanoparticles used to improve the transfection efficiency of tumor target sites; (3) used to engineer adoptively transferred cells to achieve cell tracking and promotion Nanomaterials for tumor infiltration and maintenance of in vivo functions; (4) Nanomaterials for in-situ editing of anti-tumor T cells in vivo.
In addition, the review also discussed the prospects and challenges of nanomaterials in the basic and clinical research of ACT therapy, providing references and guidelines for nanomaterial-based ACT cancer therapy.
WILEY paper information: Engineering Nano-Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment.
Chunxiong Zheng, Jiabin Zhang, Hon Fai Chan, Hanze Hu, Shixian Lv, Ning Na, Yu Tao, Mingqiang LiSmall Methods DOI: 10.
1002/smtd.
202001191 click on the bottom left Corner "Read the original text" to view the original text of the paper.
About SmallMethods Journal Small Methods, a journal of Wiley, is a high-level comprehensive journal founded in 2017.
The journal concentrates on the progress of experimental techniques related to sodium micron-scale materials, covering fields including materials science, biomedicine, chemistry, physics and other synthesis, characterization, and application technologies.
The latest impact factor is 12.
13.
Press and hold the QR code on the official WeChat platform of AdvancedScienceNewsWiley's scientific research information.
Follow us to share cutting-edge information｜Focus on scientific research trends to publish scientific research news or apply for information sharing, please contact: ASNChina@Wiley.
com
